--- title: "Rapid Micro Biosystems | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.002 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/286314455.md" datetime: "2026-05-13T20:38:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286314455.md) - [en](https://longbridge.com/en/news/286314455.md) - [zh-HK](https://longbridge.com/zh-HK/news/286314455.md) --- # Rapid Micro Biosystems | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 8.002 M Revenue: As of FY2026 Q1, the actual value is USD 8.002 M, beating the estimate of USD 7.6 M. EPS: As of FY2026 Q1, the actual value is USD -0.31, missing the estimate of USD -0.2467. EBIT: As of FY2026 Q1, the actual value is USD -13.47 M. #### Revenue Total revenue for Rapid Micro Biosystems, Inc. increased by 11.1% to $8.0 million in the first quarter of 2026, up from $7.2 million in the first quarter of 2025, specifically $8,002 thousand in Q1 2026 compared to $7,205 thousand in Q1 2025. Product revenue increased by 36.0% to $5.6 million in Q1 2026, from $4.1 million in Q1 2025, amounting to $5,578 thousand in Q1 2026 compared to $4,101 thousand in Q1 2025. Service revenue declined by 21.9% to $2.4 million in Q1 2026, from $3.1 million in Q1 2025, primarily due to lower validation activity, with figures of $2,424 thousand in Q1 2026 compared to $3,104 thousand in Q1 2025. Recurring revenue increased by 27.7% to $5.1 million in Q1 2026, compared to $4.0 million in Q1 2025, and comprised 63% of total revenue in Q1 2026. #### Cost of Revenue and Gross Margin Total cost of revenue increased by 12.2% to $7.6 million in Q1 2026, from $6.8 million in Q1 2025, specifically $7,631 thousand in Q1 2026 compared to $6,801 thousand in Q1 2025. Cost of product revenue was $6,025 thousand in Q1 2026, compared to $5,029 thousand in Q1 2025. Cost of service revenue was $1,606 thousand in Q1 2026, compared to $1,772 thousand in Q1 2025. Gross margin for Q1 2026 was $0.4 million, or 4.6%, compared to $0.4 million, or 5.6%, in Q1 2025, with specific figures of $371 thousand in Q1 2026 compared to $404 thousand in Q1 2025. Product gross margin percentage increased by 15-percentage points, and consumable gross margin increased by 33-percentage points in Q1 2026. #### Operating Expenses Total operating expenses increased by 17.9% to $14.2 million in Q1 2026, compared to $12.1 million in Q1 2025, amounting to $14,223 thousand in Q1 2026 compared to $12,065 thousand in Q1 2025. Research and development expenses decreased by 7.3%, amounting to $3,359 thousand in Q1 2026, down from $3,624 thousand in Q1 2025. Sales and marketing expenses increased by 24.4%, amounting to $3,422 thousand in Q1 2026, up from $2,751 thousand in Q1 2025. General and administrative expenses increased by 30.8%, amounting to $7,442 thousand in Q1 2026, up from $5,690 thousand in Q1 2025. #### Operational Metrics Rapid Micro Biosystems, Inc. placed 6 Growth Direct systems in Q1 2026, compared to 3 systems in Q1 2025. The company completed the validation of 5 customer systems in Q1 2026, compared to 9 validations in Q1 2025. #### Net Loss Loss from operations was - $13,852 thousand in Q1 2026, compared to - $11,661 thousand in Q1 2025. Net loss for Q1 2026 was - $14.3 million, compared to a net loss of - $11.3 million in Q1 2025, specifically - $14,275 thousand in Q1 2026 compared to - $11,263 thousand in Q1 2025. Net loss per share was - $0.31 in Q1 2026, compared to - $0.26 in Q1 2025. #### Cash and Investments Cash, cash equivalents, short-term investments, and restricted cash were approximately $23 million as of March 31, 2026, compared to $38,580 thousand as of December 31, 2025. Cash and cash equivalents were $13,815 thousand as of March 31, 2026, compared to $20,030 thousand as of December 31, 2025. Short-term investments were $9,134 thousand as of March 31, 2026, compared to $18,266 thousand as of December 31, 2025. Restricted cash was $284 thousand as of March 31, 2026, and December 31, 2025. #### Full Year 2026 Outlook Rapid Micro Biosystems, Inc. reaffirms its full year 2026 total revenue guidance range of $37.0 million to $41.0 million. This guidance includes 30 to 38 Growth Direct system placements and at least 25 system validations. The company also projects a full year 2026 gross margin percentage of approximately 20%, with a Q4 2026 exit rate in the mid-20% range. ### Related Stocks - [RPID.US](https://longbridge.com/en/quote/RPID.US.md) ## Related News & Research - [Rapid Micro Biosystems Announces Pricing of Up to Approximately $32 Million Underwritten Offering | RPID Stock News](https://longbridge.com/en/news/286840649.md) - [Rapid Micro Biosystems Raises $8.9M Net in Underwritten Offering, Adds $140K D&O Purchase](https://longbridge.com/en/news/286969296.md) - [Rapid Micro Biosystems Faces ESG-Related Reputational and Operational Risks Amid Evolving Sustainability Rules](https://longbridge.com/en/news/279111558.md) - [21:59 ETACROBiosystems fördert Innovationen bei JPM Spotlight-Sessions von bioSeedin und unterstützt strategisch den Aufbau globaler Partnerschaften](https://longbridge.com/en/news/275692064.md) - [Microbix Shareholders Back Board Slate and Auditor at Annual Meeting](https://longbridge.com/en/news/280626227.md)